These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 15563478)

  • 1. Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate.
    Koenig W; Twardella D; Brenner H; Rothenbacher D
    Clin Chem; 2005 Feb; 51(2):321-7. PubMed ID: 15563478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of renal function in intensive care: plasma cystatin C vs. creatinine and derived glomerular filtration rate estimates.
    Le Bricon T; Leblanc I; Benlakehal M; Gay-Bellile C; Erlich D; Boudaoud S
    Clin Chem Lab Med; 2005; 43(9):953-7. PubMed ID: 16176176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of N-terminal pro-B-natriuretic peptide, C-reactive protein, and creatinine clearance for prognosis in patients with known coronary heart disease.
    Rothenbacher D; Koenig W; Brenner H
    Arch Intern Med; 2006 Dec 11-25; 166(22):2455-60. PubMed ID: 17159010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study.
    Ix JH; Shlipak MG; Chertow GM; Whooley MA
    Circulation; 2007 Jan; 115(2):173-9. PubMed ID: 17190862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kidney dysfunction and fatal cardiovascular disease--an association independent of atherosclerotic events: results from the Health, Aging, and Body Composition (Health ABC) study.
    Deo R; Fyr CL; Fried LF; Newman AB; Harris TB; Angleman S; Green C; Kritchevsky SB; Chertow GM; Cummings SR; Shlipak MG;
    Am Heart J; 2008 Jan; 155(1):62-8. PubMed ID: 18082491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genotype and plasma concentration of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events.
    Loew M; Hoffmann MM; Koenig W; Brenner H; Rothenbacher D
    Arterioscler Thromb Vasc Biol; 2005 Jul; 25(7):1470-4. PubMed ID: 15860739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cystatin C and the risk of death and cardiovascular events among elderly persons.
    Shlipak MG; Sarnak MJ; Katz R; Fried LF; Seliger SL; Newman AB; Siscovick DS; Stehman-Breen C
    N Engl J Med; 2005 May; 352(20):2049-60. PubMed ID: 15901858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cystatin C: a marker of renal function or something more?
    Curhan G
    Clin Chem; 2005 Feb; 51(2):293-4. PubMed ID: 15681558
    [No Abstract]   [Full Text] [Related]  

  • 9. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease.
    Shlipak MG; Katz R; Sarnak MJ; Fried LF; Newman AB; Stehman-Breen C; Seliger SL; Kestenbaum B; Psaty B; Tracy RP; Siscovick DS
    Ann Intern Med; 2006 Aug; 145(4):237-46. PubMed ID: 16908914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of cystatin C with poor exercise capacity and heart rate recovery: data from the heart and soul study.
    McManus D; Shlipak M; Ix JH; Ali S; Whooley MA
    Am J Kidney Dis; 2007 Mar; 49(3):365-72. PubMed ID: 17336697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cystatin C identifies cardiovascular risk better than creatinine-based estimates of glomerular filtration in middle-aged individuals without a history of cardiovascular disease.
    Svensson-Färbom P; Ohlson Andersson M; Almgren P; Hedblad B; Engström G; Persson M; Christensson A; Melander O
    J Intern Med; 2014 May; 275(5):506-21. PubMed ID: 24279862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship of cystatin C, creatinine, estimated GFR, and cardiovascular events.
    Zhang L; Ni L; Lv J
    J Huazhong Univ Sci Technolog Med Sci; 2010 Dec; 30(6):699-703. PubMed ID: 21181357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Change in Multiple Filtration Markers and Subsequent Risk of Cardiovascular Disease and Mortality.
    Rebholz CM; Grams ME; Matsushita K; Inker LA; Foster MC; Levey AS; Selvin E; Coresh J
    Clin J Am Soc Nephrol; 2015 Jun; 10(6):941-8. PubMed ID: 25825481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glomerular filtration rate estimation in patients with advanced chronic renal insufficiency based on serum cystatin C levels.
    Schück O; Teplan V; Jabor A; Stollova M; Skibova J
    Nephron Clin Pract; 2003; 93(4):c146-51. PubMed ID: 12759583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers of kidney function and prediction of death from cardiovascular and other causes in the elderly: A 9-year follow-up study.
    Salminen M; Laine K; Korhonen P; Wasen E; Vahlberg T; Isoaho R; Kivelä SL; Löppönen M; Irjala K
    Eur J Intern Med; 2016 Sep; 33():98-101. PubMed ID: 27370901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relations between markers of renal function, coronary risk factors and the occurrence and severity of coronary artery disease.
    Wang J; Sim AS; Wang XL; Salonikas C; Moriatis M; Naidoo D; Wilcken DE
    Atherosclerosis; 2008 Apr; 197(2):853-9. PubMed ID: 17826782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum cystatin C is a more sensitive and more accurate marker of glomerular filtration rate than enzymatic measurements of creatinine in renal transplantation.
    Christensson A; Ekberg J; Grubb A; Ekberg H; Lindström V; Lilja H
    Nephron Physiol; 2003; 94(2):p19-27. PubMed ID: 12845219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma cystatin-C and development of coronary heart disease: The PRIME Study.
    Luc G; Bard JM; Lesueur C; Arveiler D; Evans A; Amouyel P; Ferrieres J; Juhan-Vague I; Fruchart JC; Ducimetiere P;
    Atherosclerosis; 2006 Apr; 185(2):375-80. PubMed ID: 16046222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of cystatin C- and creatinine-based definitions of chronic kidney disease to cardiovascular risk assessment in 20 population-based and 3 disease cohorts: the BiomarCaRE project.
    Rothenbacher D; Rehm M; Iacoviello L; Costanzo S; Tunstall-Pedoe H; Belch JJF; Söderberg S; Hultdin J; Salomaa V; Jousilahti P; Linneberg A; Sans S; Padró T; Thorand B; Meisinger C; Kee F; McKnight AJ; Palosaari T; Kuulasmaa K; Waldeyer C; Zeller T; Blankenberg S; Koenig W;
    BMC Med; 2020 Nov; 18(1):300. PubMed ID: 33161898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cystatin C as a risk factor for outcomes in chronic kidney disease.
    Menon V; Shlipak MG; Wang X; Coresh J; Greene T; Stevens L; Kusek JW; Beck GJ; Collins AJ; Levey AS; Sarnak MJ
    Ann Intern Med; 2007 Jul; 147(1):19-27. PubMed ID: 17606957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.